Posted: November 28, 2008

RCP Therapeutics Appoints Professor Weissig to its Scientifc Advisory Board

(Nanowerk News) RCP Therapeutics, a biopharmaceuticals company specialising in the converging nanotechnology and regenerative medical markets, announces the appointment of Professor Volkmar Weissig to the Company’s Scientific Advisory Board.
Volkmar Weissig is Associate Professor of Pharmacology at the Department of Pharmaceutical Sciences, Midwestern University College of Pharmacy, Glendale, Arizona, whilst previously serving as Assistant Professor of Pharmaceutics at Northeastern University, Boston, Massachusetts. In particular, the presence of Professor Weissig enhances RCP Therapeutics’ scientific expertise in the field of nano-carrier assisted sub-cellular targeting and mitochondrial nanomedicine.
RCP Therapeutics has a lead therapeutic candidate that targets the mitochondria of cancer cells to evade multi-drug resistance and this forms a core element of the company’s research and development programme.
The Company’s pioneering technology also treats injuries resulting from stroke ischemia and reperfusion injury, which is expected to begin clinical trials in 2009. Furthermore, RCP Therapeutics has identified and performed early stage trials using a p53 nanoparticle to treat the effects of restenosis following angioplasty. The Company aggregates intellectual property, performs early stage proof of concept in pre-clinical and clinical trials and seeks to penetrate markets, and drives revenues through collaborative partnership with pharmaceutical companies in later stage clinical studies.
To date, RCP Therapeutics has identified a series of product candidates and pilot launched first product, Bimene, a novel nano-cosmeceutical skincare product, utilising its nanoparticle delivery platform acquired via licenses from universities and US based research institutions.
Commenting on the appointment, Robert Sexauer: CEO of RCP Therapeutics expressed: “We are very pleased that Professor Weissig is joining our Scientific Advisory Board, especially as he is recognised as one of the pre-eminent scientists in the realm of sub-cellular targeting and mitochondrial nanomedicine. Indeed, our company is driving innovations in this field. Professor Weissig has been recently interviewed by MIT Technology Review to discuss our licensed technology that was demonstrated to be more effective in treating cancers than existing alternatives by virtue of the fact that reformulated anti-cancer chemotherapy with mitochondrial subcellular targeting ligand is able to bypass or evade cancer multi-drug resistance mechanisms and instruct cancer cells to commit suicide. This is a novel cancer targeting strategy that was shown to be more effective and made those regular anti-cancer chemotherapies much less toxic than the non-targeting strategy. We plan to further develop our technologies, take our products through clinical trials and ultimately bring them to market – so delivering a real breakthrough in cancer drug treatment. Professor Weissig will be part of that critical process.”
About RCP Therapeutics, Ltd.
RCP Therapeutics, Ltd is a regenerative medicine company focused on commercialising its proprietary nanotechnologies into large markets with unmet clinical needs and improving patient outcomes.
The Company is actively developing and optimising pioneering regenerative, curative, and preventative biomedical technologies and therapeutic products to treat and prevent human diseases. In early stage studies conducted at the Cleveland Clinic in 2008, RCP’s lead product candidate, nano SOD, demonstrated highly desirable efficacy in reducing the effects of stroke and reperfusion injury. The company is hoping to begin Phase 1 clinical trials in 2009. Stroke is the 3rd leading cause of death in the United States and a cause of serious, long-term disability. Website:
About Professor Volkmar Weissig
Volkmar Weissig, Sc.D., Ph.D., Associate Professor of Pharmacology, received his B.S., M.S. and Ph.D. degrees in Chemistry and his post doctoral Sc.D. degree in Biochemistry and Pharmaceutical Biotechnology from the Martin-Luther University in Halle (Germany). He completed several years of postdoctoral fellowships at the Cardiology Research Centre in Moscow (Russia), at the Academic Department of Medicine at the Royal Free Hospital School of Medicine in London (UK), at the Institute of Organic Chemistry at the Czechoslovakian Academy of Science in Prague (CSFR), at the College of Pharmacy and the College of Medicine at the University of Florida, Gainesville, FL and at Harvard Medical School and Massachusetts General Hospital in Boston, MA.
Before joining the faculty at Midwestern University, he was an Assistant Professor of Pharmaceutical Sciences at Northeastern University in Boston, MA. Dr. Weissig holds 16 patents and has published over 60 research papers, review articles and book chapters, mostly in the area of nano drug delivery systems. Several of his book chapters have been translated into Chinese, German and Polish. More recently, he has turned his scientific focus on Mitochondrial Pharmaceutics, an area he actively has been pioneering for the last 10 years.
He serves as the Associate Editor of the “Journal of Liposome Research” and he is also an Editorial Board Member of the “Journal of Biomedical Nanotechnology”, of “Medicinal Chemistry” and of “Cancer Nanotechnology: Basic, Translational, and Clinical Research".. He is frequently invited to speak at international scientific conferences. In 2004, Dr. Weissig was elected as Vice Chairman and the following year as Chairman of the American Association of Pharmaceutical Science’s Northeast Regional Discussion Group (AAPS-NERDG). He also is an active member of the International Liposome Society, the Mitochondrial Research Society, the Controlled Release Society, the American Society for Gene Therapy and the American Society for Advancement of Science.
Source: LayTec GmbH
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: